Improvement of liver disease and inflammation in patients with advanced HCV-related cirrhosis after antiviral therapy

Luz M MEDRANO
Instituto de Salud Carlos III

Juan BERENGUER
Hospital General Universitario Gregorio Maranon

Sergio SALGUERO
Instituto de Salud Carlos III

Juan GONZÁLEZ-GARCÍA
Hospital Universitario La Paz

Cristina DÍEZ
Hospital General Universitario Gregorio Maranon

Victor HONTAÑÓN
Hospital Universitario La Paz

Pilar GARCÍA-BRONCANO
Instituto de Salud Carlos III

Luis IBAÑEZ-SAMANIEGO
Hospital General Universitario Gregorio Maranon

José M BELLÓN
Hospital General Universitario Gregorio Maranon

Mª Ángeles JIMÉNEZ-SOUZA
Instituto de Salud Carlos III

Salvador Resino García (✉️ sresino@isciii.es)
Instituto de Salud Carlos III Campus de Majadahonda

Research

Keywords: Chronic hepatitis C, direct-acting antiviral, HIV, cirrhosis, inflammation, coagulopathy, angiogenesis

DOI: https://doi.org/10.21203/rs.3.rs-45478/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in patients with advanced HCV-related cirrhosis. We performed a prospective study of patients with advanced cirrhosis (liver decompensation or liver stiffness measurement [LSM] ≥ 25 kPa or hepatic liver pressure gradient [HVPG] ≥ 10 mmHg or Child-Pugh-Turcotte (CTP) ≥ 7) who received DAA therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Statistical analyses were performed employing Generalized Linear Mixed Models (GLMM). In this study, 62 patients (12 HCV-monoinfected and 50 HIV/HCV-coinfected) who achieved SVR were included in the analysis. We found significant decreases in LSM, HVPG, LBP, IP-10, IL-8, IL-18, IL-1RA, OPG, sVCAM-1, sICAM-1, TNFR-I, PAI-1, and VEF-A during follow-up. Variations in most outcome measures were similar as for HCV-monoinfected and HIV/HCV-coinfected patients. We found significant positive associations between changes in LBP, IP-10, MCP-1, IL-8, IL-1β, IL-18, IL-6, OPG, sVCAM-1, sICAM-1, and PAI-1 and LSM values after HCV clearance. Variations in LBP, IL-8, IL-6, IL-18, OPG, PAI-1, and D-dimer were positively associated with changes in HVPG values; and variations in IP-10, IL-1β, IL-6, TNF-α, IL-1RA, OPG, and sICAM-1 were related to changes in CTP score. In conclusion, the eradication of HCV with all-oral DAAs promoted a decrease in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis), which were positively associated with each other.

Background

Hepatitis C virus (HCV) chronically infects about 71 million people in the world (1% prevalence) [1]. Chronic hepatitis C (CHC) causes progressive liver inflammation, which promotes the development of hepatic cirrhosis after 10 to 20 years of HCV infection, with a 3–6% annual risk for hepatic decompensation among cirrhotic patients [1]. HCV infection triggers an immune response against the viral infection, but it also promotes chronic inflammation, immune activation, and immune dysfunction that accelerate the development of the liver fibrosis and other comorbidities [2, 3]. Additionally, in advanced stages, cirrhosis-associated immune dysfunction (CAID) usually appears, characterized by higher levels of inflammation, immune activation, and immunosuppression in the liver and peripheral blood [4]. The extent of CAID is directly related to the severity of liver disease and plays a decisive role in its progression to hepatic decompensation [4]. Patients with hepatic decompensation may develop complications related to portal hypertension, such as ascites, jaundice, variceal bleeding, or hepatic encephalopathy; decreasing quality of life and survival rates [1]. The introduction of direct-acting antiviral agents against HCV (DAAs) has increased sustained virologic response (SVR) rates in patients with advanced HCV-related cirrhosis, which may improve quality of life and reduce morbidity from cirrhosis [5]. Additionally, significant decreases in liver disease scores [liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG) or Child-Pugh-Turcotte (CTP)] [6–14] and plasma biomarkers related to
inflammation and immune activation [15–20] have been described in HCV-monoinfected patients after SVR with all-oral DAAs.

The human immunodeficiency virus (HIV) co-infects a large number of patients infected with HCV since both viruses share the same routes of transmission [21]. HIV infection accelerates the course of CHC, resulting in higher rates of cirrhosis, end-stage liver disease, and death when compared to HCV-monoinfected patients [22]. In HIV/HCV-coinfected patients, HIV infection increases a series of negative factors such as HCV replication, HCV-induced hepatic inflammation, hepatocyte apoptosis, and microbial translocation, while it also leads to a deterioration of the specific immune responses against HCV [23, 24]. Antiretroviral therapy (ART) delays the progression of fibrosis and reduces clinical complications among HIV/HCV-coinfected patients, but despite suppressive ART, these patients still have abnormally high levels of plasma biomarkers related to bacterial translocation, immune activation, inflammation and coagulation [24], which are related to higher morbidity and mortality [25]. Similarly, DAA treatments against HCV infection also achieve elevated SVR rates [26, 27] and delay CHC progression in HIV/HCV-coinfected patients [28, 29]. Several reports have also shown a significant decrease in plasma biomarkers related to inflammation and immune activation after SVR with all-oral DAAs in HIV/HCV-coinfected patients [18, 30–34]. However, DAA therapy alone does not completely block uncontrolled inflammation and liver injury, particularly with advanced liver disease [35]. Thus, some cirrhotic patients who achieve SVR with DAAs remain at risk of cirrhosis progression and developing hepatocellular carcinoma [2].

Despite many reports that have shown significant decreases in liver disease scores and plasma biomarkers after SVR with DAAs therapy, there still is a lack of consistency in the characteristics of these studies, such as the time points after completion of HCV treatment and statistical analyses used, as well as the biomarkers analyzed and identified to be statistically different and liver disease stage of the patients included.

In this study, we assessed changes in liver disease scores (LSM, HVPG, and CTP) and plasma biomarkers related to inflammation, coagulopathy, and angiogenesis in patients with advanced HCV-related cirrhosis following SVR with all-oral DAAs, as well as the association between the changes in the two set of markers during the follow-up.

**Patients And Methods**

**Patients**

We carried out a multicenter prospective study of 62 patients with advanced HCV-related cirrhosis who started anti-HCV therapy with all-oral DAAs, 12 HCV-monoinfected patients (HCV-group) and 50 HIV/HCV-coinfected patients (HIV/HCV-group). Patients were recruited at four tertiary referral hospitals in Madrid (Spain) between January 2015 and June 2016 (ESCORIAL study; see Appendix). This study was approved by the Research Ethics Committee of the Instituto de Salud Carlos III (CEI PI 41_2014) and was...
conducted according to the Declaration of Helsinki. All participants gave their written consent before enrollment.

The inclusion criteria were: 1) active HCV infection at baseline defined by detectable plasma HCV-RNA; 2) advanced cirrhosis (prior history of liver decompensation (ascites, bleeding esophageal varices, hepatic encephalopathy), or LSM ≥25 kPa, or HVPG ≥10 mmHg or CTP ≥7); 3) starting anti-HCV therapy with all-oral DAAs (without interferon (IFN) or ribavirin) and achieving a SVR defined as an undetectable HCV-RNA load 12 weeks after finalization of anti-HCV therapy.

From 97 patients included in the ESCORIAL study and with plasma sample at baseline, 35 were lost to follow-up (2 deaths, 6 abandonment of the study, 2 virologic failure, and 25 unavailable at the end of follow-up (48 weeks after completing HCV therapy)). Therefore, 62 patients were included in the study: 12 HCV-monoinfected patients (HCV-group) and 50 HIV/HCV-coinfected patients (HIV/HCV-group).

Clinical data

Epidemiological and clinical data were collected through an online form, which fulfilled the confidentiality requirements. These data were monitored to verify that all the information in the database matched the patients’ records.

The LSM was carried out by trained operators of transient elastography (FibroScan®, Echosens, Paris, France), as we previously described [36]. LSM values were reported in kilopascals (kPa) and range from 2.5 to 75 kPa. The CTP score was calculated from five factors (total bilirubin, albumin, international normalized ratio, ascites, and encephalopathy) and range from 5 to 15 points. Hemodynamic studies were performed after overnight fasting under light sedation with intravenous midazolam, as we previously described [37]. The HVPG was measured as the difference between wedged hepatic venous pressure and free hepatic venous pressure in millimeters of mercury (mmHg).

Enzyme-linked immunosorbent assays

The Spanish HIV Hospital Gregorio Marañón (HGM) BioBank was responsible for collecting the biological samples and storing them until use at -80°C. Plasma biomarkers were measured by ProcartaPlexTM multiplex immunoassay (Bender MedSystems GmbH, Vienna, Austria) using a Luminex 200™ analyzer (Luminex Corporation, Austin, TX, United States) according to the manufacturer’s specifications. The plasma biomarkers measured by multiplex ELISA were: i) inflammation: IFN-γ-inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP1), interleukin (IL)-8; IL-1β, IL-18, IL-6, tumor necrosis factor alpha (TNF-α), interleukin-1 receptor antagonist (IL-1RA), soluble receptor activator of nuclear factor-kappa B ligand (sRANKL) and osteoprotegerin (OPG); ii) endothelial dysfunction: soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1); and soluble tumor necrosis factor receptor 1 (sTNFR-1); iii) coagulopathy: plasminogen activator inhibitor-1 (PAI-1)
and D-dimer; iv) angiogenesis: vascular endothelial growth factor A (VEGF-A) and soluble receptor 1 for vascular endothelial growth factor (sVEGF-R1). Because a high proportion of the analyzed samples were below the lower limit of detection, we used the raw fluorescence intensity values in arbitrary units, without subtracting blank, as a relative quantification of the analyte abundances [38].

We also used commercial simple ELISA assays for biomarkers that were not available by multiplex ELISA: Lipopolysaccharide binding protein (LBP) (R&D Systems, Minneapolis, USA), soluble CD14 (sCD14) and fatty acid binding protein 2 (FABP-2) (Raybiotech, Georgia, USA). The lipopolysaccharide (LPS; Hycult Biotech, Uden, The Netherlands) was evaluated by a Limulus amebocyte lysate chromogenic endpoint ELISA.

**Statistical analysis**

Stata 15.0 (StataCorp, Texas, USA) and SPSS 22.0 (SPSS INC, Chicago, IL, USA) were used to perform the statistical analyses. All p-values were two-tailed and were corrected for multiple testing to reduce the risk of a spurious result by using the false discovery rate with Benjamini and Hochberg (q-values). The statistical significance was defined as \( p \leq 0.05 \) or \( q \leq 0.05 \), as appropriate.

Categorical variables were analyzed by the Chi-square test or Fisher’s exact test, as required. Continuous variables were analyzed by Mann-Whitney U test (independent groups). Moreover, we used Generalized Linear Mixed Models (GLMM) with a gamma distribution (log-link) to evaluate repeated measurements. Gamma distribution in GLMM is recommended for modeling skewed continuous outcomes. The log-link was applied only to the outcome measure or dependent variable (y), which were the severity scores of liver cirrhosis and plasma biomarkers values. Our model only included two factors or independent variables (x), group (HIV/HCV-group vs HCV-group) that is the between-subject effect and time (basal vs final) that is the within-subject factor time. The interaction between group and time was taken into account. This analysis gives us the estimation of average increase (\( \Delta x = \text{final value} (x_2) - \text{baseline value} (x_1) \)) of each biomarker in each of the two study groups. GLMM models were also used to analyze the association between the change in plasma biomarkers (\( \Delta x \)) and the changes in severity scores of liver disease (\( \Delta y \)) during the follow-up. This analysis gives us the regression coefficient (\( \beta \)), which indicates the size and direction of the effect, according to your positive or negative sign.

Finally, GLMM was used to evaluate whether the change in outcome measures (liver disease scores and plasma biomarkers values) during the follow-up was similar between the HIV/HCV group and HCV group (impact of HIV infection). In this case, GLMM was adjusted by the most relevant patient’s characteristics at baseline: gender, age, alcohol consumer, intravenous drug user, previous IFN therapy, HCV genotype, \( \log_{10} \) HCV RNA, and statins. This analysis gives us an estimate of the difference between the increments for each group (\( \Delta x \)).

**Results**
Baseline characteristics of patients

Table 1 shows the epidemiological and clinical characteristics of the 62 patients with advanced HCV-related cirrhosis (12 HCV-monoinfected and 50 HIV/HCV-coinfected patients). The HIV/HCV-group were younger (p-value=0.002) and had less percentage of patients previously treated with IFN therapy (p-value=0.021), but had a higher percentage of intravenous drug users (p-value<0.001). All HIV/HCV-coinfected patients were on ART and plasma HIV viral load was undetectable (<50 copies/mL). None of the participants were actively using injection drugs.

Baseline values of the outcome measures

Table 2 shows the baseline values of the analyzed markers in this study. Regarding liver disease, the HIV/HCV-group had a lower percentage of patients with CTP≥7 (p-value=0.014) and lower values of sCD14 (p-value=0.001), FABP-2 (p-value=0.009), and sRANKL (p-value=0.029) than HCV-monoinfected patients. However, only the difference in sCD14 remained statistically significant after an adjustment for multiple comparisons (q-value=0.029).

Change in outcome measures after achieving SVR

The changes in the outcome measures during the follow-up for all patients are shown in Figure 1 (full description in Additional File 1 & 2). We found significant decreases in severity scores of liver disease [LSM (q-value<0.001) and HVPG (q-value=0.005)] and plasma biomarkers [LBP (q-value=0.001), IP-10 (q-value<0.001), IL-8 (q-value<0.001), IL-1β (q-value=0.035), IL-18 (q-value<0.001), IL-1RA (q-value=0.015), OPG (q-value<0.001), sVCAM-1 (q-value<0.001), sICAM-1 (q-value<0.001), TNFR-I (q-value=0.041), PAI-1 (q-value<0.001), and VEGF-A (q-value=0.002)].

We also analyzed the study population stratified by HIV coinfection (see Additional File 3). The HCV-group showed significant decreases only in IP-10 (q-value=0.001), sICAM-1 (q-value<0.001) and PAI-1 (q-value=0.019), while five other markers (LSM, IL-18, TNF-α, OPG, and sVCAM-1) were close to statistical significance (p-value≤0.05 and q-value≤0.1). The HIV/HCV-group showed significant decreases in LSM (q-value<0.001), HVPG (q-value=0.011), CTP (q-value=0.045), LBP (q-value<0.001), IP-10 (q-value<0.001), IL-8 (q-value<0.001), IL-18 (q-value<0.001), IL-1RA (q-value=0.013), OPG (q-value<0.001), sVCAM-1 (q-value<0.001), sICAM-1 (q-value<0.001), PAI-1 (q-value=0.001), and VEF-A (q-value=0.006)].

We used an adjusted GLMM to assess whether there were differences in the change of outcome measures during the follow-up between the two study groups (HIV/HCV-group vs HCV-group). In this case, significant differences between groups were found in CTP (p-value=0.002) and TNFR-I (p-value=0.012), but these differences disappeared after correcting for multiple testing (see Additional File 4). This indicates that changes during the follow-up in outcome measures were very similar between the HIV/HCV-group and the HCV-group for most markers.
Association between changes in plasma biomarkers and liver disease scores after reaching SVR

The summary of associations between the change in values of plasma biomarkers and severity scores of liver disease is shown in Figure 2 (full description in Additional File 5). For LSM values (Figure 2A), we found a significant positive association with LBP (q-value<0.001), IP-10 (q-value<0.001), MCP-1 (q-value=0.016), IL-8 (q-value<0.001), IL-1β (q-value=0.001), IL-18 (q-value=0.001), IL-6 (q-value<0.001), OPG (q-value<0.001), sVCAM-1 (q-value<0.001), and sICAM-1 (q-value<0.001), and PAI-1 (q-value=0.001). For HVPG values (Figure 2B), we found significant positive associations with LBP (q-value=0.048), IL-8 (q-value=0.006), IL-1β (q-value=0.030), IL-18 (q-value=0.048), IL-6 (q-value=0.006), OPG (q-value=0.006), PAI-1 (q-value=0.030), and D-dimer (q-value=0.006). For CTP values (Figure 2C), we found significant positive associations with IP-10 (q-value=0.005), IL-1β (q-value=0.009), IL-6 (q-value<0.001), TNF-α (q-value=0.011), IL-1RA (q-value=0.024), OPG (q-value=0.027), and sICAM-1 (q-value=0.015).

Discussion

In this study, the major findings in patients with advanced HCV-related cirrhosis were: i) HCV eradication with all-oral DAAs promoted an improvement in liver disease scores and plasma biomarkers (inflammation, coagulopathy, and angiogenesis); ii) HIV infection showed a slight impact on the evolution of outcome measures analyzed (liver disease scores and plasma biomarkers), since the evolution of the two study groups (HIV/HCV-coinfected and HCV-monoinfected patients) was similar; and iii) the decreases in plasma biomarkers (inflammation and coagulopathy) were associated with decreases in liver disease severity scores. Therefore, our data suggest HCV elimination with all-oral DAAs was linked to a significant improvement in liver disease scores and plasma biomarkers related to inflammation, coagulopathy, and angiogenesis in patients with advanced cirrhosis, with there being a relation between both changes. Our results could shed light on the evolution of patients with advanced HCV-related cirrhosis after HCV eradication with all-oral DAAs, irrespective of HIV infection.

Both HIV and HCV infection and advanced cirrhosis promote inflammation, immune activation, and dysfunction of the immune system, which are all linked to a greater severity of liver disease and the development of comorbidities [2–4]. Bacterial translocation in patients with advanced HCV-related cirrhosis is a key step in the pathogenesis of spontaneous bacterial peritonitis and bacteremia as well as a main factor that triggers the immune activation and inflammation, which in turn promotes hemodynamic changes and the development of decompensated cirrhosis [4]. Endothelial dysfunction is also promoted by inflammation and is linked to the progression of CHC and the development of cardiovascular events [39]. Moreover, hepatocytes release most of the proteins in the blood, where plasma levels can be altered by CHC progression, promoting an increase in thrombotic risk [40]. Coagulopathy is related to increased risk of disease progression and death in HIV-infected patients [41] and patients with advanced liver disease [42]. In a recent article on HIV/HCV-coinfected patients, we showed that plasma biomarkers of bacterial translocation, inflammation, endothelial dysfunction, and
coagulopathy increased with the increase of liver fibrosis severity, particularly in patients with LSM ≥ 40 KPa [36]. However, the eradication of HCV with antiviral therapy can stop this pathological process of the liver, at least almost entirely [35]. Additionally, the decrease in inflammation biomarker levels could also indicate a lower risk of developing comorbidities in cirrhotic patients who achieved SVR with DAA therapy [2, 25].

In our study overall, HCV clearance after DAA therapy promoted a significant improvement in severity scores of liver cirrhosis and many plasma biomarkers linked to inflammation (bacterial translocation, inflammatory response, and endothelial dysfunction) and coagulopathy. Our data are in concordance with a large number of previous studies that found a significant decrease in liver disease scores of HIV/HCV-coinfected patients [6, 7, 32, 43–45] and HCV-monoinfected patients [6–14] after HCV eradication with DAA therapy; and also in plasma biomarkers of HIV/HCV-coinfected patients [18, 30–34] and HCV-monoinfected patients [15–20]. However, there is an important lack of consistency in these previous publications regarding the plasma biomarkers and liver severity scores evaluated, time-points used to take data or samples after the end of HCV treatment, statistical analysis used, and liver fibrosis stages included. In our study, a high number of markers were found to be significant despite the small sample size, and others might be masked due to limited statistical power. In addition and notably, other factors provided robustness to our study, such as its prospective design (repeated measures), the evaluation of changes in markers at 48 weeks after treatment completion (medium-term), the higher suitability of the statistical analysis (GLMM), and the fact that all the patients had advanced cirrhosis. Our analysis of VEGF-A, which plays a key role in liver cancer angiogenesis [46], revealed an interesting observation. Previous reports did not find any change in plasma VEGF-A values [43, 47] or showed a significant increase [48] after HCV eradication with DAA therapy. However, our data suggest a discontinuation in the process of angiogenesis and a shift towards an "antiangiogenic" profile, since we observed a significant decrease in VEGF-A levels after HCV therapy with DAAs therapy.

Previously published studies do not usually have a control group of HCV-monoinfected patients, or if they do, they do not analyze the impact of HIV infection on the evolution of plasma biomarkers and liver disease scores after HCV eradication with all-oral DAAs [18, 30–34]. In our study, baseline values of outcome measures (plasma biomarkers and liver disease scores) and their subsequent evolution after DAA therapy were very similar in HIV/HCV-coinfected and HCV-monoinfected patients. Therefore, HIV infection only showed a slight impact on the outcome measures in our cohort of patients with advanced HCV-related cirrhosis, both at baseline and during follow-up after HCV eradication with AAD. This fact is remarkable because HIV infection promotes a faster progression of chronic hepatitis C [22] and higher plasma levels of markers linked to bacterial translocation, immune activation, inflammation and coagulation, despite suppressive ART [24]. It is probable that the absence of relevant differences between groups may be due to the fact that all of our patients had advanced stages of cirrhosis, where CAID is usually found, characterized by elevated immune activation, inflammation, and dysregulation of the immune system [4]. Additionally, Corma-Gómez et al. [49] have recently reported that HIV coinfection is not related to a higher risk for developing liver complications in HCV-infected patients with advanced fibrosis, who achieved SVR with IFN-free regimens. Malin et al [50] observed that the LSM regression after
successful DAA therapy did not differ in patients with HCV/HIV coinfection and those with HCV monoinfection.

The relationship between plasma biomarkers (bacterial translocation, inflammatory response, endothelial dysfunction, coagulopathy, and angiogenesis) and liver disease scores (LSM, HVPG, and CTP) has been scarcely explored in patients with advanced cirrhosis after HCV eradication with DAAs. Laursen et al. [20] reported that the levels of macrophage activation markers (sCD163 and soluble mannose receptor) correlated with LSM values during follow-up in HCV-monoinfected patients. Kostadinova et al. [32] showed that an improvement in LSM values correlated with a decrease in sCD14 levels after IFN-free HCV therapy. Additionally, plasma levels of sCD163, IL-6, and Mac2-binding protein correlated with changes in AST level and APRI score. In our study, the decreases in several plasma biomarkers levels linked to bacterial translocation, inflammatory response, endothelial dysfunction, and coagulopathy were directly associated with the decreases in liver disease scores (LSM, HVPG, and CTP) after HCV eradication with DAAs. Therefore, our data suggest a relation between improvement in liver cirrhosis and resolution of inflammation after HCV eradication with all-oral DAAs.

Conclusions

In conclusion, eradication of HCV with all-oral DAAs in patients with advanced HCV-related cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis), in both HIV/HCV-coinfected and HCV-monoinfected patients. Changes in these plasma biomarkers related to inflammation were positively associated with an improvement in liver disease scores.

Abbreviations

Hepatitis C virus (HCV)

Chronic hepatitis C (CHC)

Cirrhosis-associated immune dysfunction (CAID)

Direct-acting antiviral agents (DAAs)

Sustained virologic response (SVR)

Liver stiffness measurement (LSM)

Hepatic liver pressure gradient (HVPG)

Child-Pugh-Turcotte (CTP)

Human immunodeficiency virus (HIV)
Combination antiretroviral therapy (ART)

Kilopascals (kPa)

Millimeter of mercury (mmHG)

Soluble CD14 (sCD14)

Lipopolysaccharide (LPS)

Fatty acid-binding protein 2 (FABP2)

Lipopolysaccharide binding protein (LBP)

IFN-γ-inducible protein 10 (IP-10)

Monocyte chemoattractant protein-1 (MCP1)

Interleukin (IL)

Tumor necrosis factor alpha (TNF-α)

Interleukin-1 receptor antagonist (IL-1RA)

Soluble receptor activator of nuclear factor-kappa B ligand (sRANKL)

Osteoprotegerin (OPG)

Soluble vascular cell adhesion molecule 1 (sVCAM1)

Soluble intercellular cell adhesion molecule 1 (sICAM1)

Soluble tumor necrosis factor receptor 1 (sTNFR1)

Plasminogen activator inhibitor-1 (PAI-1)

Vascular endothelial growth factor A (VEGF-A)

Soluble receptor 1 for vascular endothelial growth factor (sVEGF-R1)

Generalized Linear Mixed Models (GLMM)

Interferon (IFN)

Appendix

The ESCORIAL study group.
Hospital General Universitario Gregorio Marañón (Madrid, Spain): Cristina Díez, Luis Ibáñez, Leire Pérez-Latorre, Diego Rincón, Teresa Aldámiz-Echevarría, Vega Catalina, Pilar Miralles, Francisco Tejerina, María C Gómez-Rico, Esther Alonso, José M Bellón, Rafael Bañares, and Juan Berenguer.

Hospital Universitario La Paz/IdiPAZ (Madrid, Spain): José Arribas, José I Bernardino, Carmen Busca, Javier García-Samaniego, Víctor Hontañón, Luz Martín-Carbonero, Rafael Micán, María L Montes-Ramírez, Victoria Moreno, Antonio Olveira, Ignacio Pérez-Valero, Eulalia Valencia, and Juan González-García.

Hospital Universitario Puerta de Hierro (Madrid, Spain): Elba Llop and José Luis Calleja.

Hospital Universitario Ramón y Cajal (Madrid, Spain): Javier Martínez and Agustín Albillos.

Fundación SEIMC/GeSIDA (Madrid, Spain): Marta de Miguel, María Illescas, and Herminia Esteban.

Declarations

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee of the Instituto de Salud Carlos III (CEI PI 41_2014).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study may be available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI14/01581 and PI17/00903 to JGG, CP17CIII/00007 and PI18CIII/00028 to MAJS, and PI14CIII/00011 and PI17CIII/00003 to SR). The study was also funded by the
Acknowledgments

This study would not have been possible without the collaboration of all the patients, medical and nursery staff and data managers who have taken part in the project. We want to acknowledge the support of the Spanish HIV HGM BioBank for the collection of biological samples and their storage.

Author contributions

Conceptualization: SR, JB, and JGG.

Data curation: JB, JGG, CD, VH, PGB, LIS.

Formal analysis: LMM, SS, JMB, SR, and MAJS.

Funding acquisition: JB, JGG, MAJS, and SR.

Investigation and methodology: LMM and PGB.

Project Administration: JB.

Supervision and visualization: SR.

Writing – original draft preparation: MAJS and SR.

Writing – Review & Editing: LMM and JB.

All authors have read and approved the final manuscript.

References

1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–32.

2. Naggie S. Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. Top Antivir Med. 2017;25(1):3–6.

3. Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509–23.
4. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–96.

5. Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J. 2019;7(5):642–50.

6. Fernandes FF, Piedade J, Guimaraes L, Nunes EP, Chaves U, Goldenzon RV, Cardoso SW, Duarte J, Grinsztejn B, Veloso VG, et al: Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. J Gastroenterol Hepatol 2019.

7. Macias J, Granados R, Tellez F, Merino D, Perez M, Morano LE, Palacios R, Paniagua M, Frias M, Merchante N, et al. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. J Viral Hepat. 2019;26(1):16–24.

8. Lee YC, Hu TH, Hung CH, Lu SN, Chen CH, Wang JH. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. PLoS One. 2019;14(4):e0214323.

9. Afadhla N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24(10):823–31.

10. Lens S, Alvarado-Tapias E, Marino Z, Londono MC, Martinez ELL, Fortea J, Ibanez JI, Ariza L, Baiges X. A et al: Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology. 2017;153(5):1273–83 e1271.

11. Mandorfer M, Kozbial K, Schwabl P, Freimuth C, Schwarzer R, Stern R, Chromy D, Stattermayer AF, Reiberger T, Beinhardt S, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692–9.

12. Gentile I, Scorto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13(1):66–74.

13. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018;154(8):2111–21 e2118.

14. McCaughan GW, Thwaites PA, Roberts SK, Strasser SI, Mitchell J, Morales B, Mason S, Gow P, Wigg A, Tallis C, et al. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD >/= 15). Aliment Pharmacol Ther. 2018;47(3):401–11.

15. Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2018;48(11–12):1301–11.

16. Nien HC, Hsu SJ, Su TH, Yang PJ, Sheu JC, Wang JT, Chow LP, Chen CL, Kao JH, Yang WS. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by
17. Lattanzi B, Baroncelli S, De Santis A, Galluzzo CM, Mennini G, Michelini Z, Lupo M, Ginanni Corradini S, Rossi M, Palmisano L, et al. Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients. Aliment Pharmacol Ther. 2018;48(10):1146–55.

18. Mascia C, Vita S, Zuccala P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, et al. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One. 2017;12(6):e0179400.

19. Saraiva GN, do Rosario NF, Medeiros T, Leite PEC, Lacerda GS, de Andrade TG, de Azeredo EL, Ancuta P, Almeida JR, Xavier AR, et al. Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C. Mediators Inflamm. 2018;2018:8578051.

20. Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, Moller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Gronbaek H. Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat 2019.

21. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356(14):1445–54.

22. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369–79.

23. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362–71.

24. Abutaleb A, Sherman KE. A changing paradigm: management and treatment of the HCV/HIV-co-infected patient. Hepatol Int. 2018;12(6):500–9.

25. Hunt PW, Lee SA, Siedner MJ. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016;214(Suppl 2):44–50.

26. Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67(3):847–57.

27. Pol S, Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations". Liver Int. 2018;38(Suppl 1):28–33.

28. Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Tellez MJ, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55(5):728–36.

29. Berenguer J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Tellez MJ, Quereda C, et al. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. 2017;66(2):344–56.
30. Carlton-Smith C, Holmes JA, Naggie S, Lidofsky A, Lauer GM, Kim AY, Chung RT. of the AAsg: IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. J Viral Hepat. 2018;25(5):465–72.

31. Lopez-Cortes LF, Trujillo-Rodriguez M, Baez-Palomino A, Benmarzouk-Hidalgo OJ, Dominguez-Molina B, Milanes-Guisado Y, Espinosa N, Viciana P, Gutierrez-Valencia A. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018;218(4):624–32.

32. Kostadinova L, Shive CL, Zebrowski E, Fuller B, Rife K, Hirsch A, Compan A, Moreland A, Falck-Ytter Y, Popkin DL, et al. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathog Immun. 2018;3(1):149–63.

33. Parisi SG, Andreis S, Mengoli C, Menegotto N, Cavinato S, Scaggiante R, Andreoni M, Palu G, Basso M, Cattelan AM. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. Med Microbiol Immunol. 2018;207(3–4):183–94.

34. Najafi Fard S, Schietroma I, Corano Scheri G, Giustini N, Serafino S, Cavallari EN, Pinacchio C, De Girolamo G, Ceccarelli G, Scagnolari C, et al. Direct-acting antiviral therapy enhances total CD4 + and CD8 + T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol. 2018;42(4):319–29.

35. Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018;24(47):5297–311.

36. Medrano LM, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, Jimenez-Sousa MA, Guardiola JM, Crespo M, Quereda C, Sanz J, Canorea I, et al. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. Aids. 2018;32(9):1095–105.

37. Rincon D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, Salcedo M, Matilla A, Senosiain M, Clemente G, et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48(4):487–95.

38. Breen EJ, Tan W, Khan A. The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays. Sci Rep. 2016;6:26996.

39. Akcam FZ, Tigli A, Kaya O, Ciris M, Vural H. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J Interferon Cytokine Res. 2012;32(12):570–4.

40. Gonzalez-Reimers E, Quintero-Platt G, Martin-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol. 2016;22(18):4427–37.

41. Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS. 2013;8(2):117–24.
42. Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med. 2011;19(3):121–5.

43. Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45(1):139–49.

44. Navarro J, Laguno M, Vilchez HH, Guardiola JM, Carrion JA, Force L, Cairo M, Cifuentes C, Vilaro J, Cucurull J, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017;72(10):2850–6.

45. Navarro J, Laguno M, Vilchez HH, Guardiola JM, Carrion JA, Force L, Cairo M, Cifuentes C, Vilaro J, Cucurull J, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017;72(10):2850–6.

46. Navarro J, Laguno M, Vilchez HH, Guardiola JM, Carrion JA, Force L, Cairo M, Cifuentes C, Vilaro J, Cucurull J, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017;72(10):2850–6.

47. Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, Andreani S, Vandelli G, Bernabucci V, Lei B, et al. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology. 2018;68(3):1010–24.

48. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G, Serviddio G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One. 2016;11(12):e0167934.

49. Corma-Gomez A, Morano L, Tellez F, Rivero-Juarez A, Real LM, Alados JC, Rios-Villegas MJ, Vera-Mendez FJ, Munoz RP, Geijo P, et al. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. Aids. 2019;33(7):1167–74.

50. Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, et al. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. HIV Med. 2019;20(3):230–6.

Tables

Table 1. Summary of characteristics of patients with advanced HCV-related cirrhosis at baseline.
|                        | All (62) | HCV (12) | HIV/HCV (50) | \(p\)   |
|------------------------|----------|----------|--------------|---------|
| **No.**                | 62       | 12       | 50           |         |
| Gender (male)          | 47 (75.8%) | 8 (66.7%) | 39 (78%) | 0.411   |
| Age (years)            | 52.9 (48.9; 55.8) | 59.9 (54.3; 71.3) | 52.2 (48.8; 54.1) | 0.002   |
| Smoker                 |          |          |              |         |
| Never                  | 10 (16.4%) | 4 (33.3%) | 6 (12.2%) | 0.111   |
| Previously (≥ 6 months)| 16 (26.2%) | 4 (33.3%) | 12 (24.5%) |         |
| Currently              | 35 (57.4%) | 4 (33.3%) | 31 (63.3%) |         |
| Alcohol intake         |          |          |              |         |
| Never                  | 29 (46.8%) | 8 (66.7%) | 21 (42%) | 0.232   |
| Previously (≥ 6 months)| 28 (45.2%) | 4 (33.3%) | 24 (48%) |         |
| Currently              | 5 (8.1%) | 0 (0%) | 5 (10%) |         |
| IVDU                   |          |          |              | <0.001  |
| Never                  | 24 (38.7%) | 12 (100%) | 12 (24%) |         |
| Previously (≥ 6 months)| 38 (61.3%) | 0 (0%) | 38 (76%) |         |
| Currently              | 0 (0%) | 0 (0%) | 0 (0%) |         |
| Treatments             |          |          |              |         |
| Previous IFNα therapy  | 33 (53.2%) | 10 (83.3%) | 23 (46%) | 0.021   |
| Statins                | 9 (14.5%) | 1 (8.3%) | 8 (16%) | 0.498   |
| Antiretroviral therapy |          |          |              |         |
| NRTI+NNRTI-based       | -        | -        | 7 (14.3%) |         |
| NRTI+II-based          | -        | -        | 24 (49%) |         |
| NRTI+PI-based          | -        | -        | 6 (12.2%) |         |
| PI+II+others-based     | -        | -        | 4 (8.2%) |         |
| Others                 | -        | -        | 8 (16.3%) |         |
| HIV markers            |          |          |              |         |
| Prior AIDS             | -        | -        | 18 (36%) |         |
| Nadir CD4+ T-cells     |          |          |              |         |
| (cells/mm\(^3\))      | -        | -        | 114.7 (70; 182) |         |
| Nadir CD4+ <200 cells/mm\(^3\) | - | - | 35 (76.1%) |         |
| CD4+ T-cells (cells/mm\(^3\)) | - | - | 439 (234; 721) |         |
| CD4+ <500 cells/mm\(^3\) | - | - | 30 (60%) |         |
| HCV markers            |          |          |              | 0.231   |
| HCV genotype           |          |          |              |         |
| 1                      | 42 (68.9%) | 10 (83.3%) | 32 (65.3%) |         |
| 3                      | 9 (14.8%) | 2 (16.7%) | 7 (14.3%) |         |
| 4                      | 10 (16.4%) | 0 (0%) | 10 (20.4%) |         |
| Log\(_{10}\) HCV-RNA (IU/mL) | 6.2 (5.7; 6.7) | 6.2 (5.6; 6.4) | 6.2 (5.7; 6.7) | 0.569   |
| HCV-RNA ≥850.000 IU/mL | 41 (66.1%) | 8 (66.7%) | 33 (66%) | 0.965   |

**Statistics:** Values are expressed as absolute number (percentage) and median (interquartile range). \(p\)-values were calculated by Chi-square, Fisher’s exact test, and Mann-Whitney tests, as required.

**Abbreviations:** HCV, hepatitis C virus; HIV, human immunodeficiency virus; IVDU, intravenous drug user; IFNα, interferon-alpha; NRTI, nucleoside analogue HIV reverse; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor;
II, integrase inhibitor; AIDS, acquired immune deficiency syndrome; HCV-RNA, HCV plasma viral load.

Table 2. Summary of severity scores of liver disease and plasma biomarkers in patients with advanced HCV-related cirrhosis at baseline.
| Liver disease markers | All | HCV | HIV/HCV | P-values | q-values |
|-----------------------|-----|-----|---------|----------|----------|
| LSM (kPa)             | 31.6 (23.4; 40.7) | 29.9 (27; 66.4) | 32.8 (22.3; 39.3) | 0.293 | 0.397 |
| <25 kPa               | 16 (26.7%) | 2 (18.2%) | 14 (28.6%) | 0.582 | 0.703 |
| 25-40 kPa             | 29 (48.3%) | 5 (45.4%) | 24 (49%) | 0.293 | 0.397 |
| ≥40 kPa               | 15 (25%) | 4 (36.4%) | 11 (22.4%) | 0.293 | 0.397 |
| CTP                   | 5 (5; 6) | 5 (5; 7) | 5 (5; 5) | 0.107 | 0.255 |
| CTP ≥7                | 6 (10.3%) | 3 (33.3%) | 3 (6.1%) | 0.014 | 0.135 |
| HCVG (mmHg)           | 17.8 (13.5; 20.5) | 15 (11; 17) | | 0.123 | 0.255 |
| <16 mmHg              | 15 (48.4%) | 2 (25%) | 13 (56.5%) | 0.117 | 0.255 |
| 16-20 mmHg            | 29 (48.3%) | 5 (45.4%) | 24 (49%) | 0.293 | 0.397 |
| ≥=20 mmHg             | 15 (25%) | 4 (36.4%) | 11 (22.4%) | 0.293 | 0.397 |

| Plasma biomarkers     |         |     |         |         |          |
|-----------------------|---------|-----|---------|----------|----------|
| Bacterial translocation |       |     |         |         |          |
| LPS (EU/ml)           | 0.9 (0.7; 1.2) | 0.8 (0.5; 0.9) | 0.9 (0.7; 1.4) | 0.058 | 0.240 |
| LBP (µg/ml)           | 1 (0.6; 1.4) | 0.7 (0.6; 1.1) | 1.1 (0.7; 1.5) | 0.087 | 0.255 |
| sCD14 (µg/ml)         | 2.1 (1.6; 3.2) | 3.2 (2.5; 4.9) | 2 (1.6; 2.3) | 0.001 | 0.029 |
| FABP-2 (ng/ml)        | 0.4 (0.1; 0.7) | 0.8 (0.2; 1.6) | 0.3 (0.1; 0.5) | 0.009 | 0.131 |

| Inflammation          |         |     |         |         |          |
|-----------------------|---------|-----|---------|----------|----------|
| IP-10 (a.u.)          | 1221.5 (865.3; 1799.5) | 1413.5 (1117; 2083.8) | 1180.3 (807.8; 1706) | 0.209 | 0.319 |
| MCP-1 (a.u.)          | 493.8 (276.1; 684.1) | 548.3 (211; 750.5) | 481.5 (289.6; 684.1) | 0.845 | 0.904 |
| IL-8 (a.u.)           | 117.8 (74.6; 185.8) | 84.5 (63.3; 158.1) | 127 (80.8; 188.4) | 0.196 | 0.316 |
| IL-1β (a.u.)          | 15 (13; 27.6) | 16.3 (12.1; 63.5) | 15 (13; 20.4) | 0.809 | 0.904 |
| IL-18 (a.u.)          | 988.5 (573.1; 1670.9) | 710 (461.4; 1333.8) | 1116.3 (584.8; 1697.9) | 0.301 | 0.397 |
| IL-6 (a.u.)           | 65.3 (33.8; 156.3) | 156.8 (48; 417.4) | 59 (32.9; 114.5) | 0.052 | 0.240 |
| TNF-α (a.u.)          | 9.8 (7.4; 12) | 10 (7.9; 15.5) | 9 (7; 12) | 0.381 | 0.480 |
| IL-1RA (a.u.)         | 18 (13; 25.9) | 18.5 (14.1; 22.3) | 18 (13; 27.5) | 0.865 | 0.904 |
| sRANKL (a.u.)         | 24.3 (19; 36.4) | 31 (24.6; 39) | 22.5 (18.4; 36.4) | 0.029 | 0.168 |
| OPG (a.u.)            | 217.5 (158.5; 307) | 282.5 (220; 334.8) | 195.5 (151.5; 286.1) | 0.069 | 0.250 |

| Endothelial dysfunction |         |     |         |         |          |
|------------------------|---------|-----|---------|----------|----------|
| sVCAM-1 (a.u.)         | 10747 (8616.8; 12142.3) | 9285 (8580.8; 11099.6) | 10916 (9008.3; 12352.1) | 0.288 | 0.159 |
| sICAM-1 (a.u.)         | 107.8 (63.5; 163.1) | 71.5 (43.6; 139.9) | 111.3 (68.8; 165.1) | 0.134 | 0.259 |
| TNFR-1 (a.u.)          | 32 (20.4; 57.8) | 24.5 (16.8; 38) | 33.5 (20.9; 76.5) | 0.255 | 0.255 |

| Coagulopathy          |         |     |         |         |          |
|-----------------------|---------|-----|---------|----------|----------|
| PAI-1 (a.u.)          | 1054.8 (808.6; 1315.3) | 1132.5 (628; 1463.1) | 1036 (833.4; 1315.3) | 0.915 | 0.915 |
| D-dimer (a.u.) | 1767.5 (653.4; 4289.9) | 2738 (924.6; 9896.5) | 1717 (559.8; 3627.6) | 0.187 | 0.316 |
|---------------|------------------------|----------------------|----------------------|--------|--------|
| Angiogenesis  |                        |                      |                      |        |        |
| VEGF-A (a.u.)| 76 (57.6; 90.8)        | 72 (54.5; 111)       | 76 (57.6; 90)        | 0.873  | 0.904  |
|               | 44.5 (32.4; 69.5)      | 59.5 (40.4; 83.1)    | 42 (31.6; 66.9)      | 0.107  | 0.255  |

**Statistics:** Values are expressed as absolute number (percentage) and median (interquartile range). *P*-values were calculated by Chi-square, Fisher’s exact test, and Mann-Whitney test, as required. *P*-values, raw *p*-values; *q*-values, *p*-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure. The statistically significant differences are shown in bold.

**Abbreviations:** HCV, hepatitis C virus; HIV, human immunodeficiency virus; LSM, liver stiffness measure; kPa, kilopascal; HVPG, Hepatic Venous Pressure Gradient; mmHg, millimetre of mercury; CTP, Child-Pugh-Turcotte; a.u., arbitrary units of fluorescence; sCD14, soluble CD14; LPS, lipopolysaccharide; FABP2, fatty acid-binding protein 2; LBP, lipopolysaccharide binding protein; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; TNF-α, tumor necrosis factor alpha; IP-10, IFN-γ-inducible protein 10; MCP1, monocyte chemoattractant protein-1; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-kappa B ligand; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNFR-1, soluble tumor necrosis factor receptor 1; PAI-1, plasminogen activator inhibitor-1; VEGF-A; vascular endothelial growth factor A; sVEGF-R1, soluble receptor1 for vascular endothelial growth factor.

**Figures**
Figure 1

Change in severity scores of liver disease and plasma biomarkers during follow-up in patients with advanced HCV-related cirrhosis. Statistics: Values are expressed as the estimated average of the increase ($\Delta x=x_2-x_1$) and 95% of confidence interval (95%CI). P-values were calculated by GLMM models. P-values, raw p-values; q-values, p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure. The statistically significant differences are shown in bold. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; LSM, liver stiffness measurement; CTP, Child-Pugh-Turcotte; HVPG, hepatic venous pressure gradient; mmHg, millimeter of mercury; kPa, kilopascals; a.u., arbitrary units of fluorescence; sCD14, soluble CD14; LPS, lipopolysaccharide; FABP2, fatty acid-binding protein 2; LBP, lipopolysaccharide binding protein; IL,
interleukin; IL-1RA, interleukin-1 receptor antagonist; TNF-α, tumor necrosis factor alpha; IP-10, IFN-γ-inducible protein 10; MCP1, monocyte chemoattractant protein-1; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-kappa B ligand; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNFR-1, soluble tumor necrosis factor receptor 1; PAI-1, plasminogen activator inhibitor-1; VEGF-A; vascular endothelial growth factor A; sVEGF-R1, soluble receptor1 for vascular endothelial growth factor.

**Figure 2**

Association between the change in values of plasma biomarkers and severity scores of liver disease during HCV treatment in patients with advanced HCV-related cirrhosis. Statistics: Values are expressed as regression coefficient (β) and 95% of confidence interval (95%CI). P-values were calculated by GLMM models. P-values, raw p-values; q-values, p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure. The statistically significant differences are shown in bold. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; LSM, liver stiffness measures; CPT, Child-Pugh-Turcotte; KVPG, hepatic venous pressure gradient (mmHg); a.u., arbitrary units of fluorescence; sCD14, soluble CD14; LPS, lipopolysaccharide; FABP2, fatty acid-binding protein 2; LBP, lipopolysaccharide binding protein; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; TNF-α, tumor necrosis factor alpha; IP-10, IFN-γ-inducible protein 10; MCP1, monocyte chemoattractant protein-1; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-kappa B ligand; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNFR-1, soluble tumor necrosis factor receptor 1; PAI-1, plasminogen activator inhibitor-1; VEGF-A; vascular endothelial growth factor A; sVEGF-R1, soluble receptor1 for vascular endothelial growth factor.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AdditionalFile5.docx
- AdditionalFile4.docx
- AdditionalFile3.docx
- AdditionalFile2.docx
- AdditionalFile1.docx